» Articles » PMID: 12823080

Chlorpromazine Equivalent Doses for the Newer Atypical Antipsychotics

Overview
Specialty Psychiatry
Date 2003 Jun 26
PMID 12823080
Citations 736
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Several clinical and research applications require an estimation of therapeutic dose equivalence across antipsychotic medications. Since the advent of the newer atypical antipsychotics, new dose equivalent estimations have been needed.

Method: The reported minimum effective dose was identified for each newer atypical antipsychotic medication and for haloperidol across all available fixed-dose placebo-controlled studies. Reported minimum effective dose equivalence ratios to haloperidol were then converted to chlorpromazine equivalents using the "2 mg of haloperidol equals 100 mg of chlorpromazine" convention.

Data Sources And Study Selection: To identify the fixed-dose studies, the following sources were searched until June 2002: MEDLINE, the bibliographies of identified reports, published meta-analyses and reviews, Cochrane reviews, Freedom of Information Act material available from the Food and Drug Administration, and abstracts from several scientific meetings from 1997 to 2002.

Results: Doses equivalent to 100 mg/day of chlorpromazine were 2 mg/day for risperidone, 5 mg/day for olanzapine, 75 mg/day for quetiapine, 60 mg/day for ziprasidone, and 7.5 mg/day for aripiprazole.

Conclusion: These equivalency estimates may be useful for clinical and research purposes. The source of the dose equivalency estimation is evidence-based and consistent across medication.

Citing Articles

Poor self-reported sleep is associated with prolonged white matter T2 relaxation in psychotic disorders.

Yesilkaya U, Chen X, Watford L, McCoy E, Sen M, Genc I Front Psychiatry. 2025; 15():1456435.

PMID: 39839134 PMC: 11747379. DOI: 10.3389/fpsyt.2024.1456435.


Does fragmented sleep mediate the relationship between deficits in sleep spindles and memory consolidation in schizophrenia?.

Mylonas D, Patel R, Larson O, Zhu L, Vangel M, Baxter B Sleep Adv. 2025; 6(1):zpae090.

PMID: 39811395 PMC: 11725649. DOI: 10.1093/sleepadvances/zpae090.


The role of ferroptosis and oxidative stress in cognitive deficits among chronic schizophrenia patients: a multicenter investigation.

Peng Z, Jia Q, Mao J, Jiang S, Ma Q, Luo X Schizophrenia (Heidelb). 2025; 11(1):4.

PMID: 39799168 PMC: 11724852. DOI: 10.1038/s41537-025-00555-8.


Association Between Dynapenia/Sarcopenia, Extrapyramidal Symptoms, Negative Symptoms, Body Composition, and Nutritional Status in Patients with Chronic Schizophrenia.

Kamoi R, Mifune Y, Soriano K, Tanioka R, Yamanaka R, Ito H Healthcare (Basel). 2025; 13(1.

PMID: 39791654 PMC: 11720556. DOI: 10.3390/healthcare13010048.


2D Flower-like CdS@Co/Mo-MOF as Co-Reaction Accelerator of g-CN-Based Electrochemiluminescence Sensor for Chlorpromazine Hydrochloride.

Fan X, Zhang G, Li X, Wang Y, Wang Y, Hao S Biosensors (Basel). 2024; 14(12).

PMID: 39727852 PMC: 11674348. DOI: 10.3390/bios14120586.